Additionally, the launch of emerging therapies, ongoing Research and Development (R&D) activities, and the active participation of the global pharma and biotech giants in the therapeutic segment, will also influence the market growth. Several key companies are active in the therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.
DelveInsight’s “Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Muscle Invasive Bladder Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Non-Muscle Invasive Bladder Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Non-Muscle Invasive Bladder Cancer (NMIBC): An Overview
Non-muscle invasive bladder cancer (NMIBC), formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder, wherein the bladder muscle is not involved.
Approximately 70–80% of patients with newly diagnosed bladder cancer present with a form of non-muscle-invasive bladder cancer (NMIBC), such as non-invasive papillary tumor (pTa), carcinoma in situ (CIS; pTis), or early invasive tumor (non-muscle invasive; pT1).
Non-Muscle Invasive Bladder Cancer (NMIBC) Market Key Facts
-
The total diagnosed prevalent population of NMIBC in the seven major markets was found to be 533,263 in 2017, which is expected to increase for the study period, i.e., 2017–2030.
-
In 2017, the diagnosed prevalent population of low-grade NMIBC patients was 136,822 and high-grade NMIBC patients were 76,962 in the US.
-
Among the European 5 countries, Germany had the highest diagnosed prevalence of NMIBC, followed by Italy and Spain. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of NMIBC.
-
In Japan, the diagnosed prevalent population of NMIBC was 74,691 in 2017.
Non-Muscle Invasive Bladder Cancer (NMIBC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Muscle Invasive Bladder Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Non-Muscle Invasive Bladder Cancer market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Segmentation
-
Prevalent cases of Bladder Cancer
-
Diagnosed Prevalent cases of Bladder Cancer
-
Age-specific Diagnosed Prevalence of NMIBC
-
Diagnosed Prevalent cases of NMIBC
-
Tumour stage-specific Diagnosed Prevalence of NMIBC
-
Grade-specific Diagnosed Prevalence of NMIBC
-
Risk-specific Diagnosed Prevalence of NMIBC
Non-Muscle Invasive Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to get launched during the study period. The analysis covers Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Muscle Invasive Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Analysis
The high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) pipeline possesses potential drugs in mid and late-stage developments. The launch of emerging therapies will create a significant positive shift in the NMIBC market size.
Some of the key companies in the Non-Muscle Invasive Bladder Cancer (NMIBC) Market include:
-
Viventia Bio
-
Sesen Bio
-
FKD Therapies Oy
-
Ferring Pharmaceuticals
-
CG Oncology
-
ImmunityBio
-
Altor Biosciences
-
Theralase
-
Merck
And several others
Non-Muscle Invasive Bladder Cancer (NMIBC) Therapies covered in the report include:
-
Vicinium
-
Adstiladrin
-
CG0070
-
N-803 (ALT-803)
-
TLD-1433
-
Keytruda
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Non-Muscle Invasive Bladder Cancer Competitive Intelligence Analysis
4. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance
5. Non-Muscle Invasive Bladder Cancer Disease Background and Overview
6. Non-Muscle Invasive Bladder Cancer Patient Journey
7. Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population
8. Non-Muscle Invasive Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Muscle Invasive Bladder Cancer Unmet Needs
10. Key Endpoints of Non-Muscle Invasive Bladder Cancer Treatment
11. Non-Muscle Invasive Bladder Cancer Marketed Products
12. Non-Muscle Invasive Bladder Cancer Emerging Therapies
13. Non-Muscle Invasive Bladder Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Non-Muscle Invasive Bladder Cancer Market Outlook (7 major markets)
16. Non-Muscle Invasive Bladder Cancer Access and Reimbursement Overview
17. KOL Views on the Non-Muscle Invasive Bladder Cancer Market.
18. Non-Muscle Invasive Bladder Cancer Market Drivers
19. Non-Muscle Invasive Bladder Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Reports by DelveInsight
Pneumothorax Treatment Devices Market
“Pneumothorax Treatment Devices Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Pneumothorax Treatment Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Pneumothorax Treatment Devices market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/